
Ultimovacs is a biotech company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the nearly universal cancer antigen telomerase, investigated in five randomized Phase 2 trials. UV1 is being developed as a therapeutic cancer vaccine for use in combination with other immuno-oncology drugs, which require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe, Australia, and the USA; Five Phase II trials…
Annual RevenueBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Estimated OwnershipPublicMatching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.